Primary Record
Cediranib
- In stock
- 8,369 g
- Purity
- 98.8 %
- CAS
- 288383-20-0
Compound Identifiers & Properties
- CAS
- 288383-20-0
- PubChem CID
- 9933475
- SMILES
- CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5
- Canonical SMILES
- COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Names & Synonyms
- Cediranib
- Recentin
- 288383-20-0
- Cedirannib
- AZD2171
- cediranibum
- Chelocardin
- Cadiranib
- Cediranib free base
- Cediranib (AZD2171)
- Cediranib?
- Cediranib [INN]
- Cediranib maleate
- Cediranib (maleate)
- Cediranib (AZD217)
- AZD-2171
- AZD-2171 maleate
- Kinome_3318
- NQU9IPY4K9
- Cediranib (Standard)
- Cediranib (USAN/INN)
- Cediranib,AZD2171
- UNII-NQU9IPY4K9
- AZD 2171
- Cediranib dihydrochloride
- AZD2171, Cediranib
- MFCD09954115
- CEDIRANIB [USAN]
- RefChem:574948
- Cediranib - AZD2171
- Cediranib [USAN:INN:BAN]
- C25H27FN4O3
- CEDIRANIB [MART.]
- D09VMI
- CEDIRANIB [WHO-DD]
- CHEMBL491473
- SCHEMBL63147
- cc-438
- MLS006010063
- DTXSID10183035
- GTPL5664
- orb1305389
- QCR-93
- SCHEMBL29351458
- SCHEMBL29368143
- SCHEMBL29383181
- AZD2171, Recentin, Cediranib
- Cediranib (AZD2171)/Recentin
- CHEBI:94782
- ZD-2171
- 288383-20-0 (free base)
- AOB1949
- DTXCID20105526
- L01XE32
- 4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline
- XXJWYDDUDKYVKI-UHFFFAOYSA-N
- BCPP000295
- GLXC-02838
- HMS3654G05
- HMS3674G17
- HMS3744O21
- AMY16021
- BCP01378
- EX-A2039
- KS-00000LF1
- ZINC3948085
- ABP000861
- AN-567
- BDBM50331096
- EBC-11323
- HY-10205R
- NSC755606
- NSC800069
- s1017
- 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline
- 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
- AKOS005145767
- ACN-034651
- BCP9000500
- CCG-264679
- CID9933475
- CS-0119
- DB04849
- ES-0052
- FC32854
- NSC-732208
- NSC-755606
- NSC-800069
- RL02984
- SB16536
- SDCCGSBI-0654326.P001
- ZD 2171
- M6294
- NCGC00263097-01
- NCGC00263097-09
- NCGC00263097-11
- AC-25033
- AK340948
- AT-19598
- BC667561
- HY-10205
- SC-23199
- SMR004701223
- SY102459
- 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
- AB0030443
- A1882
- FT-0751000
- NS00069640
- SW219261-1
- X2636
- EC-000.2328
- J2.560.640J
- A10185
- A24280
- D08881
- W-5429
- P111005
- Q5057052
- BRD-K86930074-001-01-9
- BRD-K86930074-001-05-0
- Quinazoline,4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-
- 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline
- B2693-065171
- 557795-03-6
- 857036-77-2
- 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline
- US brand name: Recentin. Foreign brand name: Recentin. Code name: AZD2171.AZD 2171
- 4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline (2Z)-but-2-enedioate
- 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline (2Z)-but-2-enedioate (1:1)
- 4-((4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY)-6-METHOXY-7-(3-PYRROLIDIN-1-YLPROPOXY)QUINAZOLINE
- 4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-yl-propoxy)-quinazoline
- 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline
- 4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline; 4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline; 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline; ZD 2171; AZD 2171
- 4-[(4-Fluoro-2-methyl-1H-indole-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline
- 4-[(4-fluoro-2-methyl-3H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
- AV3
- Quinazoline, 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(1-pyrrolidinyl)propoxy)-
- Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-